Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gold Fields Limited (GFI) vs Twist Bioscience Corp (TWST) Price & Performance

Gold Fields LimitedTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Gold Fields Limited vs Twist Bioscience Corp — how do they compare? Gold Fields Limited trades at $32.29 (market cap $29.07B), while Twist Bioscience Corp trades at $91.49 (market cap $5.76B). The key difference: Gold Fields Limited is far larger — about 5× Twist Bioscience Corp's market cap, and Gold Fields Limited pays a 7.03% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

GFITWST
Market Cap
$29.07B$5.76B
Sector
Basic MaterialsHealth
52-Week High
$61.52$102.88
52-Week Low
$23.95$24.16
Enterprise Value
$30.51B$5.69B
Dividend Yield
7.03%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gold Fields Limited

Gold Fields (GFI) trades at $33.33, down 0.6% with a bearish technical signal despite strong fundamental metrics including a P/E of 8.37, net income margin of 40.76%, and ROE of 52.33%. Recent earnings show mixed results with a Q1 2025 beat but subsequent misses. The company demonstrates robust cash flow growth with 2025 operating cash flow projected at $3.8B, while technical indicators show oversold conditions with RSI at 26.87.

GFI presents a compelling value opportunity with attractive valuation multiples and exceptional profitability metrics, though recent earnings misses and bearish technical momentum create near-term uncertainty. The 57% upside to the $52.75 consensus price target suggests significant potential, but investors should monitor operational execution and gold price volatility as key risk factors.

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $92.61, up 2.5% on the day, with a bullish technical signal and strong analyst support. The company shows improving revenue growth ($377M in 2025, up 20% year-over-year) but continues to report significant losses (-$77.7M net income). Recent AI-driven drug discovery collaborations and product expansions provide growth catalysts, though persistent negative cash flow and insider selling present concerns.

Outlook remains cautiously optimistic with 79% analyst buy ratings and a $91.63 consensus target. Investment opportunity centers on AI-enabled synthetic biology growth, while risks include sustained profitability challenges, cash burn, and competitive pressures in genomics. The stock trades at premium valuations (P/S 13.74) despite negative margins.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gold Fields Limited

Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.

Read more on GFI

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST